Related Experiment Videos
Prostanoid therapy for pulmonary arterial hypertension
David B Badesch1, Vallerie V McLaughlin, Marion Delcroix
1University of Colorado Health Sciences Center, Denver, Colorado, USA. David.Badesch@UCHSC.edu
Journal of the American College of Cardiology
|June 15, 2004
Summary
Prostanoids are crucial for treating pulmonary arterial hypertension (PAH), with various delivery methods like intravenous epoprostenol and subcutaneous treprostinil showing benefits. Despite administration challenges, these therapies remain vital for PAH management.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Pulmonary Medicine
Background:
- Prostanoids are established treatments for pulmonary arterial hypertension (PAH).
- Different prostanoid compounds and administration routes (IV epoprostenol, SC treprostinil, inhaled iloprost, oral beraprost) have been investigated.
- Epoprostenol improves outcomes in severe PAH but involves complex administration.
Purpose of the Study:
- To review the role and efficacy of various prostanoids in pulmonary arterial hypertension (PAH) treatment.
- To compare the benefits and delivery complexities of different prostanoid therapies.
- To assess the impact of prostanoids on exercise capacity, hemodynamics, and survival in PAH patients.
Main Methods:
- Review of existing clinical trials and therapeutic strategies involving prostanoids for PAH.
- Analysis of data on intravenous epoprostenol, subcutaneous treprostinil, inhaled iloprost, and oral beraprost.
- Evaluation of treatment outcomes including exercise capacity, hemodynamic parameters, and survival rates.
Main Results:
- Intravenous epoprostenol significantly improves exercise capacity, hemodynamics, and survival in severe idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with scleroderma.
- Subcutaneous treprostinil offers benefits but is limited by side effects at the infusion site.
- Inhaled iloprost shows promise for lung-selective effects, improving functional class and exercise tolerance.
- Oral beraprost demonstrated short-term exercise capacity improvements in IPAH but lacked sustained effects on hemodynamics or survival.
Conclusions:
- Despite challenges with short half-lives and complex delivery systems, prostanoids remain essential in managing pulmonary arterial hypertension (PAH).
- Ongoing research aims to develop prostanoids with simpler administration routes and improved tolerability.
- The choice of prostanoid therapy depends on disease severity, patient tolerance, and administration feasibility.